ProQR Therapeutics (PRQR) Operating Income (2012 - 2026)

ProQR Therapeutics has reported Operating Income for 10 years, with the latest figure at -$16.0 million in Q1 2026.

• Quarterly Operating Income fell 40.45% year-over-year to -$16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.6 million (down 50.64% YoY) and the FY2025 annual result came in at -$50.6 million, down 55.31% from the prior year.
• Operating Income slipped to -$16.0 million in Q1 2026 per PRQR's latest filing, from -$10.6 million in the prior quarter.
• Over five years, Operating Income peaked at -$3.9 million in Q2 2024 and troughed at -$20.0 million in Q3 2022.
• A 5-year average of -$11.8 million and a median of -$10.8 million in 2024 frame the typical range for Operating Income.
• The sharpest annual moves came in 2023 and 2025: Operating Income surged 59.75% in 2023, then plunged 257.65% in 2025.
• Over 5 years, Operating Income stood at -$12.7 million in 2022, then soared by 46.95% to -$6.7 million in 2023, then slumped by 59.73% to -$10.8 million in 2024, then advanced by 1.7% to -$10.6 million in 2025, then slumped by 50.9% to -$16.0 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$16.0 million, -$10.6 million, and -$13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.